Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Other Accumulated Expenses: 2023-2024

Historic Other Accumulated Expenses for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $3.1 million.

  • BioLineRx's Other Accumulated Expenses rose 9.37% to $2.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.8 million, marking a year-over-year increase of 9.37%. This contributed to the annual value of $3.1 million for FY2024, which is 6.62% down from last year.
  • According to the latest figures from FY2024, BioLineRx's Other Accumulated Expenses is $3.1 million, which was down 6.62% from $3.4 million recorded in FY2023.
  • BioLineRx's 5-year Other Accumulated Expenses high stood at $3.4 million for FY2023, and its period low was $3.1 million during FY2024.
  • Moreover, its 2-year median value for Other Accumulated Expenses was $3.2 million (2023), whereas its average is $3.2 million.
  • Data for BioLineRx's Other Accumulated Expenses shows a maximum YoY declined of 6.62% (in 2024) over the last 5 years.
  • BioLineRx's Other Accumulated Expenses (Yearly) stood at $3.4 million in 2023, then dropped by 6.62% to $3.1 million in 2024.